|
| |
Price : 5 slide for 600 €
|
CC2 Human, lung cancer |
| |
|
|
|
|
|
|
|
| No. |
Age |
Sex |
Organ |
Diagnosis |
TNM |
Stage |
No. of
CCN2# |
| 1 |
63 |
M |
Lung |
Squamous cell carcinoma |
T2N0M0 |
ⅠB |
101 |
| 2 |
63 |
M |
Lung |
Squamous cell carcinoma |
T2N0M0 |
ⅠB |
102 |
| 3 |
45 |
M |
Lung |
Squamous cell carcinoma |
T2N3M0 |
ⅢB |
103 |
| 4 |
50 |
M |
Lung |
Squamous cell carcinoma |
T2N1M0 |
ⅡB |
104 |
| 5 |
59 |
M |
Lung |
Squamous cell carcinoma |
T2N2M0 |
ⅢA |
105 |
| 6 |
62 |
M |
Lung |
squamous cell carcinoma |
T2N2M0 |
ⅢA |
106 |
| 7 |
67 |
M |
Lung |
Squamous cell carcinoma |
T2N1M0 |
ⅡB |
107 |
| 8 |
54 |
M |
Lung |
Squamous cell carcinoma |
T2N0M0 |
ⅠB |
108 |
| 9 |
39 |
M |
Lung |
Squamous cell carcinoma |
T4N1M0 |
ⅢB |
109 |
| 10 |
58 |
M |
Lung |
Squamous cell carcinoma |
T1N0M0 |
ⅠA |
110 |
| 11 |
39 |
M |
Lung |
Squamous cell carcinoma |
T4N1M0 |
ⅢB |
111 |
| 12 |
45 |
M |
Lung |
Squamous cell carcinoma |
T1N1M0 |
Ⅱ |
112 |
| 13 |
71 |
M |
Lung |
Squamous cell carcinoma |
T2N0M0 |
ⅠB |
113 |
| 14 |
67 |
M |
Lung |
Squamous cell carcinoma |
T2N1M0 |
ⅡB |
114 |
| 15 |
65 |
M |
Lung |
Squamous cell carcinoma |
T2N1M0 |
ⅡA |
115 |
| 16 |
54 |
M |
Lung |
Adenocarcinoma |
T2N1M0 |
ⅡA |
116 |
| 17 |
52 |
M |
Lung |
Adenocarcinoma |
T4N0M0 |
ⅢB |
117 |
| 18 |
47 |
M |
Lung |
Adenocarcinoma |
T2N1M0 |
ⅡA |
118 |
| 19 |
61 |
F |
Lung |
Adenocarcinoma |
T1N1M0 |
ⅡA |
119 |
| 20 |
38 |
M |
Lung |
Adenocarcinoma |
T2N0M0 |
ⅠB |
120 |
| 21 |
58 |
M |
Lung |
Adenocarcinoma |
T3N0M0 |
ⅡB |
121 |
| 22 |
51 |
F |
Lung |
Adenocarcinoma |
T4N1M0 |
ⅢB |
122 |
| 23 |
48 |
F |
Lung |
Adenocarcinoma |
T1N0M0 |
ⅠA |
123 |
| 24 |
53 |
F |
Lung |
Adenocarcinoma |
T2N1M0 |
ⅡB |
124 |
| 25 |
67 |
M |
Lung |
Adenocarcinoma |
T2N0M0 |
ⅠB |
125 |
| 26 |
55 |
M |
Lung |
Bronchioloalveolar carcinoma |
T1N0M0 |
ⅠA |
126 |
| 27 |
59 |
F |
Lung |
Adenocarcinoma |
T1N0M0 |
ⅠA |
127 |
| 28 |
66 |
M |
Lung |
Adenocarcinoma |
T2N0M0 |
ⅠB |
128 |
| 29 |
57 |
M |
Lung |
Adenocarcinoma |
T1N0M0 |
ⅠA |
129 |
| 30 |
47 |
M |
Lung |
Adenosquamous carcinoma |
T2N2M0 |
ⅢA |
130 |
| 31 |
67 |
F |
Lung |
Adenosquamous carcinoma |
T2N0M0 |
ⅢA |
131 |
| 32 |
58 |
F |
Lung |
Adenosquamous carcinoma |
T2N0M0 |
ⅠB |
132 |
| 33 |
60 |
M |
Lung |
Adenosquamous carcinoma |
T2N2M0 |
ⅢA |
133 |
| 34 |
58 |
M |
Lung |
Bronchioloalveolar carcinoma |
T1N2M0 |
ⅢA |
134 |
| 35 |
57 |
F |
Lung |
Bronchioloalveolar carcinoma |
T2N1M0 |
ⅡB |
135 |
| 36 |
69 |
F |
Lung |
Bronchioloalveolar carcinoma |
T2N0M0 |
ⅠB |
136 |
| 37 |
44 |
F |
Lung |
Bronchioloalveolar carcinoma |
T2N0M0 |
ⅠB |
137 |
| 38 |
52 |
F |
Lung |
Bronchioloalveolar carcinoma |
T2N0M0 |
ⅠB |
138 |
| 39 |
34 |
0 |
Lung |
Bronchioloalveolar carcinoma |
T2N0M0 |
ⅠB |
139 |
| 40 |
60 |
F |
Lung |
Small cell carcinoma |
T2N0M0 |
ⅠB |
140 |
| 41 |
65 |
M |
Lung |
Small cell carcinoma |
T2N0M0 |
ⅠB |
141 |
| 42 |
60 |
M |
Lung |
Combined small cell + adenocarcinoma |
T2N1M0 |
ⅡB |
142 |
| 43 |
43 |
M |
Lung |
Large cell carcinoma |
T2N1M0 |
ⅡB |
143 |
| 44 |
56 |
M |
Lung |
Large cell carcinoma |
T2N1M0 |
ⅡB |
144 |
| 45 |
54 |
M |
Lung |
Large cell carcinoma |
T1N0M0 |
ⅠA |
145 |
| 46 |
61 |
M |
Lung |
Large cell carcinoma |
T1N1M0 |
ⅡA |
146 |
| 47 |
65 |
M |
Lung |
Large cell carcinoma |
T1N2M0 |
ⅢA |
147 |
| 48 |
63 |
M |
Lung |
Large cell carcinoma |
T2N0M0 |
ⅠB |
148 |
| 49 |
37 |
M |
Lung |
Mucoepidermoid carcinoma |
T1N0M0 |
ⅠA |
149 |
| 50 |
40 |
F |
Lung |
Mucoepidermoid carcinoma |
T2N1M1 |
Ⅳ |
150 |
| 51 |
56 |
M |
Lung |
Mucoepidermoid carcinoma |
T2N0M0 |
ⅠB |
151 |
| 52 |
26 |
M |
Lung |
Mucoepidermoid carcinoma |
T1N0M0 |
ⅠA |
152 |
| 53 |
26 |
F |
Lung |
Mucoepidermoid carcinoma |
T2N0M0 |
ⅠB |
153 |
| 54 |
56 |
F |
Lung |
Mucoepidermoid carcinoma |
T2N0M0 |
ⅠB |
154 |
| 55 |
54 |
F |
Lung |
Adenoid cystic carcinoma |
T4N1M0 |
ⅢB |
155 |
| 56 |
51 |
M |
Lung |
Adenoid cystic carcinoma |
T4N0M0 |
ⅢB |
156 |
| 57 |
45 |
M |
Lung |
Adenoid cystic carcinoma |
T3N0M0 |
ⅡB |
157 |
| 58 |
37 |
M |
Pleura |
Malignant mesothelioma |
T2N0M0 |
Ⅰ |
158 |
| 59 |
54 |
M |
Pleura |
Malignant mesothelioma |
T2N1M0 |
Ⅱ |
159 |
| 60 |
carbon |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| #: The normal tissue in CCN2 of corresponding number is from the
identical patient. |
| TNM and Stage classification : Lung carcinoma (AJCC 6th Edition) |
|
|
|
General Information of the Tissue Array Slide :
Applications
- Immunohistochemistry
- In situ hybridization, RNA or DNA
- Fluorescent in situ hybridization (FISH)
- In situ PCR, RNA or DNA
- TUNEL for apoptosis (Recommended procedures in
www.tissue-array.com -> protocol)
Storage and stability
- Individual slide is paraffin-coated and put in an air-tight pack
with inert gas.
- Tissue array slides are shipped in room temperature.
- If the slides are stored in 4 degree, they are good up to one
year.
How processed
- Tissues were initially fixed with formalin except for some of the
animal tissues.
- Then, dehydrated with gradient ethanol; typically 1 hour each
progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Microtoming in 4 µm thickness and put on silane coating slide from
Muto Pure Chemicals (Japan)
Before use
- Dry slides for 1 hour in a oven at 60 degree.
- Dewax slides in xylene for 4 minutes x 5 times
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2
times each.
- Immerse slides in tap water for 5 minutes
Slide orientation
- In most of the slides with 59 or 60 cores, the orientation is as
below unless indicated otherwise. #60 location is usually filled with carbon
for orientation.
| 1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
| 11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
19 |
20 |
| 21 |
22 |
23 |
24 |
25 |
26 |
27 |
28 |
29 |
30 |
| 31 |
32 |
33 |
34 |
35 |
36 |
37 |
38 |
39 |
40 |
| 41 |
42 |
43 |
44 |
45 |
46 |
47 |
48 |
49 |
50 |
| 51 |
52 |
53 |
54 |
55 |
56 |
57 |
58 |
59 |
60 |
|